Printer Friendly

3TC RESULTS TO BE SUBMITTED TO REGULATORY AUTHORITIES TO PROCEED TO DEFINITIVE PHASE OF TRIALS

 3TC RESULTS TO BE SUBMITTED TO REGULATORY AUTHORITIES
 TO PROCEED TO DEFINITIVE PHASE OF TRIALS
 LAVAL, Quebec, Oct. 13 /PRNewswire/ -- The most recent results obtained during Phase I/II clinical trials on BioChem Pharma Inc.'s (NASDAQ: BCHXF) anti-AIDS compound 3TC continue to be favorable. They will shortly be submitted to government health authorities in order to seek approval to proceed with Phase II/III trials, the definitive step in the regulatory approval process for 3TC.
 The data will be submitted by Glaxo to the United States Food and Drug Administration, to Canada's Health Protection Branch and to European regulatory authorities. Glaxo is managing the development of 3TC as part of a collaborative agreement with BioChem Pharma, of Laval, that also covers commercialization of the drug.
 During Phase I/II, trials have been conducted on about 200 patients in three North American and three European hospitals. During Phase II/III, required for the regulatory approval process, comparative clinical trials will initially be conducted on a larger number of patients in North American and European hospitals, planned to start early next year.
 Today in Anaheim, Calif., physicians who conducted the Phase I/II trials in both North America and Europe presented delegates to the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) with the most recent clinical results on 3TC.
 The review of surrogate markers such as CD4 cells, P24 antigen, B2 microglobulin and neopterin, shows positive trends.
 Among the clinical parameters under study, certain show patients experiencing weight gain and increased energy and appetite. These results are enhanced by the fact that no significant drug-related toxicity has been observed.
 Dr. Francesco Bellini, president and chief executive officer of BioChem Pharma, expressed satisfaction with 3TC's progress toward regulatory approval.
 "The project is on time and on target. We are satisfied with these results and very optimistic about the future of this drug," he said.
 BioChem Pharma Inc, is a pharmaceutical company dedicated to the research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases. Its shares are listed on the Montreal and Toronto stock exchanges under the symbol BCH, and on the NASDAQ stock market (BCHXF).
 -0- 10/13/92
 /CONTACT: Dr. Francesco Bellini of BioChem Pharma, 514-681-1744,


or Luc Beauregard or Michele Roy of National Public Relations, 514-843-7171, for BioChem Pharma/
 (BCHXF) CO: BioChem Pharma Inc. ST: Quebec IN: MTC SU:


PS-TS -- NY049 -- 9351 10/13/92 13:08 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 13, 1992
Words:407
Previous Article:UNITED AIRLINES 'ADOPTS' WASHINGTON'S EASTERN SENIOR HIGH SCHOOL
Next Article:PENTAIR REPORTS THIRD QUARTER 1992 RESULTS
Topics:


Related Articles
PRESENTATION OF PRELIMINARY DATA ON 3TC IN THE TREATMENT OF HIV INFECTION AT THE INTERNATIONAL CONFERENCE ON AIDS IN AMSTERDAM
IMPACT OF RILUTEK (TM) (riluzole) ON SURVIVAL IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) CONFIRMED IN MULTINATIONAL PHASE III TRIAL
AIDS Clinical Trial Group (ACTG) To Conduct Clinical Study of 141W94/VX-478, an HIV Protease Inhibitor
Phase III Pivotal Clinical Trial Begins with 141W94/VX-478, a Protease Inhibitor Designed by Vertex for Treatment of HIV Infection and AIDS
Vertex and Glaxo Wellcome Announce Pivotal Phase III Trial of HIV Protease Inhibitor 141W94 (VX-478) in Pediatric Patients
Vertex and Glaxo Wellcome Begin Third Phase III Pivotal Trial with HIV Protease Inhibitor 141W94 (VX-478)
Vertex Pharmaceuticals Reports Encouraging Preliminary Data from Phase II Clinical Study with HIV Protease Inhibitor 141W94
Triangle Pharmaceuticals Reports Data on Initial Results of FTC Phase I/II Trial
BIOCHEM PHARMA RECEIVES GO-AHEAD FROM U.S. FDA TO START PHASE I CLINICAL TRIAL WITH ITS NOVEL ANTI-HIV COMPOUND, BCH-10652

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters